FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898085613> ?p ?o ?g. }

• W2898085613 endingPage "viii285" @default.
• W2898085613 startingPage "viii285" @default.
• W2898085613 abstract "Background: The availability of multiple treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates the need to identify prognostic factors applicable to clinical practice. Variations in (PSA) levels are widely used in the monitoring of response to treatment with abiraterone acetate (AA) or enzalutamide, but are not validated as an early biomarker for overall survival (OS). Objective: To evaluate the association between early PSA changes and OS following enzalutamide or AA treatments in mCRPC. Methods: We retrospectively evaluated mCRPC patients treated with AA or enzalutamide, before or after docetaxel, in 11 reference hospitals between 2011 and 2017. A descriptive and multivariate analysis of the data was carried out in order to establish the association of PSA variations at 4 and 12 weeks (expressed as 30% and 50% percentage modifications, respectively, relative to baseline value at the start of AA or enzalutamide) with OS. Association with OS was analyzed using multivariate Cox regression and log-rank analyses. Spearman’s rho correlation coefficient (r) was calculated to evaluate the association between PSA changes at 4 and 12 weeks. Results: We analyzed 450 mCRPC patients with a median follow-up of 16 months (1-65). A 30% PSA decline at 4 weeks was associated with longer OS (30 vs 20 months; hazard ratio [HR] 0.55 (0.42-0.73), p < 0.001), as well as a 50% PSA decrease at 12 weeks (39 vs 19 months; HR 0.42 (0.31-0.56), p < 0.001). We found a detriment in survival in patients with a 30% PSA rise at 4 weeks, with shorter OS (22 vs 26 months; HR 1.5 (1.07-2.21), p = 0.025) and a 50% PSA increase at 12 weeks after starting treatment (14 vs 29 months; 2.66 (1.93-3.67) p < 0.001), in both univariate and multivariable models. The percentage PSA decline at 4 weeks was significantly correlated with the percentage PSA change at 12 weeks (r = 0.635; p < 0.001). Limitations include the retrospective design of this analysis. Conclusions: PSA changes as early as 4 weeks after enzalutamide or AA initiation are highly associated with OS in mCPRC. Prospective multicentre validation studies are needed to confirm these findings. Legal entity responsible for the study: Fernando López Campos. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest." @default.
• W2898085613 created "2018-11-02" @default.
• W2898085613 creator A5004023548 @default.
• W2898085613 creator A5009075369 @default.
• W2898085613 creator A5009395224 @default.
• W2898085613 creator A5016206131 @default.
• W2898085613 creator A5016317899 @default.
• W2898085613 creator A5028251370 @default.
• W2898085613 creator A5029292527 @default.
• W2898085613 creator A5038351166 @default.
• W2898085613 creator A5038747246 @default.
• W2898085613 creator A5047270956 @default.
• W2898085613 creator A5050203403 @default.
• W2898085613 creator A5050835714 @default.
• W2898085613 creator A5051735377 @default.
• W2898085613 creator A5054029338 @default.
• W2898085613 creator A5055183150 @default.
• W2898085613 creator A5057758878 @default.
• W2898085613 creator A5067080652 @default.
• W2898085613 creator A5085867926 @default.
• W2898085613 creator A5088888262 @default.
• W2898085613 creator A5090839826 @default.
• W2898085613 date "2018-10-01" @default.
• W2898085613 modified "2023-09-28" @default.
• W2898085613 title "Prognostic associations of early prostate-specific antigen (PSA) changes in patients with metastatic castration-resistant prostate cancer treated with with abiraterone acetate or enzalutamide" @default.
• W2898085613 doi "https://doi.org/10.1093/annonc/mdy284.028" @default.
• W2898085613 hasPublicationYear "2018" @default.
• W2898085613 type Work @default.
• W2898085613 sameAs 2898085613 @default.
• W2898085613 citedByCount "0" @default.
• W2898085613 crossrefType "journal-article" @default.
• W2898085613 hasAuthorship W2898085613A5004023548 @default.
• W2898085613 hasAuthorship W2898085613A5009075369 @default.
• W2898085613 hasAuthorship W2898085613A5009395224 @default.
• W2898085613 hasAuthorship W2898085613A5016206131 @default.
• W2898085613 hasAuthorship W2898085613A5016317899 @default.
• W2898085613 hasAuthorship W2898085613A5028251370 @default.
• W2898085613 hasAuthorship W2898085613A5029292527 @default.
• W2898085613 hasAuthorship W2898085613A5038351166 @default.
• W2898085613 hasAuthorship W2898085613A5038747246 @default.
• W2898085613 hasAuthorship W2898085613A5047270956 @default.
• W2898085613 hasAuthorship W2898085613A5050203403 @default.
• W2898085613 hasAuthorship W2898085613A5050835714 @default.
• W2898085613 hasAuthorship W2898085613A5051735377 @default.
• W2898085613 hasAuthorship W2898085613A5054029338 @default.
• W2898085613 hasAuthorship W2898085613A5055183150 @default.
• W2898085613 hasAuthorship W2898085613A5057758878 @default.
• W2898085613 hasAuthorship W2898085613A5067080652 @default.
• W2898085613 hasAuthorship W2898085613A5085867926 @default.
• W2898085613 hasAuthorship W2898085613A5088888262 @default.
• W2898085613 hasAuthorship W2898085613A5090839826 @default.
• W2898085613 hasBestOaLocation W28980856131 @default.
• W2898085613 hasConcept C121608353 @default.
• W2898085613 hasConcept C126322002 @default.
• W2898085613 hasConcept C126894567 @default.
• W2898085613 hasConcept C143998085 @default.
• W2898085613 hasConcept C185592680 @default.
• W2898085613 hasConcept C207103383 @default.
• W2898085613 hasConcept C2775832370 @default.
• W2898085613 hasConcept C2776551883 @default.
• W2898085613 hasConcept C2777899217 @default.
• W2898085613 hasConcept C2780192828 @default.
• W2898085613 hasConcept C2781190966 @default.
• W2898085613 hasConcept C2781197716 @default.
• W2898085613 hasConcept C2781406297 @default.
• W2898085613 hasConcept C44249647 @default.
• W2898085613 hasConcept C50382708 @default.
• W2898085613 hasConcept C55493867 @default.
• W2898085613 hasConcept C61367390 @default.
• W2898085613 hasConcept C71924100 @default.
• W2898085613 hasConceptScore W2898085613C121608353 @default.
• W2898085613 hasConceptScore W2898085613C126322002 @default.
• W2898085613 hasConceptScore W2898085613C126894567 @default.
• W2898085613 hasConceptScore W2898085613C143998085 @default.
• W2898085613 hasConceptScore W2898085613C185592680 @default.
• W2898085613 hasConceptScore W2898085613C207103383 @default.
• W2898085613 hasConceptScore W2898085613C2775832370 @default.
• W2898085613 hasConceptScore W2898085613C2776551883 @default.
• W2898085613 hasConceptScore W2898085613C2777899217 @default.
• W2898085613 hasConceptScore W2898085613C2780192828 @default.
• W2898085613 hasConceptScore W2898085613C2781190966 @default.
• W2898085613 hasConceptScore W2898085613C2781197716 @default.
• W2898085613 hasConceptScore W2898085613C2781406297 @default.
• W2898085613 hasConceptScore W2898085613C44249647 @default.
• W2898085613 hasConceptScore W2898085613C50382708 @default.
• W2898085613 hasConceptScore W2898085613C55493867 @default.
• W2898085613 hasConceptScore W2898085613C61367390 @default.
• W2898085613 hasConceptScore W2898085613C71924100 @default.
• W2898085613 hasLocation W28980856131 @default.
• W2898085613 hasOpenAccess W2898085613 @default.
• W2898085613 hasPrimaryLocation W28980856131 @default.
• W2898085613 hasRelatedWork W1980998207 @default.
• W2898085613 hasRelatedWork W2135620818 @default.
• W2898085613 hasRelatedWork W2568045406 @default.
• W2898085613 hasRelatedWork W2770702948 @default.
• W2898085613 hasRelatedWork W2776594178 @default.
• W2898085613 hasRelatedWork W3023947295 @default.
• W2898085613 hasRelatedWork W3181573761 @default.

• next